Factor X analog with an improved ability to be activated

Details Factor X analog with an improved ability to be activated Factor X analog with an improved ability to be activated

2005-10-25

2005-10-25

Weber, Jon (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S021800, C514S008100, C435S069100, C435S069200, C435S069600, C435S007100, C530S350000, C530S395000, C530S384000, C424S094640

Reexamination Certificate

active

06958322

ABSTRACT:
This invention describes a factor Xa analog which has a substitution of a minimum of one of the amino acid between Glu226 and Arg234 and possibly Ile235, relative to the amino acid numbering according to FIG.1, a preparation containing the activated form of the factor X analog, and a method for the production of these molecules.

REFERENCES:
patent: 4359049 (1982-11-01), Redl et al.
patent: 4501731 (1985-02-01), Tishkoff et al.
patent: 4735616 (1988-04-01), Eibl et al.
patent: 5460950 (1995-10-01), Barr et al.
patent: 5597799 (1997-01-01), Wolf
patent: 5635481 (1997-06-01), Wolf
patent: 5858658 (1999-01-01), Haemmerle et al.
patent: 6210929 (2001-04-01), Schlokat et al.
patent: 6562598 (2003-05-01), Himmelspach et al.
patent: 6573071 (2003-06-01), Himmelspach et al.
patent: 0 651 054 (1995-03-01), None
patent: WO 94/29370 (1994-12-01), None
patent: WO 98/38317 (1998-09-01), None
Bajaj, S. & Mann, K. “Simultaneous Purification of Bovine Prothrombin and Factor X”J. Biol. Chem.,Nov. 25, 1973, pp. 7729-7741, vol. 248, No. 22.
Barr, P.J. “Mammalian Subtilisins: The Long-Sought Dibasic Processing Endoproteases”Cell,1991, pp. 1-3, vol. 66.
Clackson, T. et al.PCR A Practical Approach: General Application of PCR to Gene Cloning and Manipulation,Eds. McPherson, Quirke and Taylor. 1991, pp. 187-214.
Eby, C.S. et al. “Characterizastion of the Structure and Function of the Carboxy Terminal Peptide of Human Factor X”Blood,1992, pp. 1214, vol. 80, Suppl. 1, Abstract only.
Elsinger, R.Laboratory Tests of Activated Prothrombin Complex Preparations; Activated Prothrombin Complex Concentrates.1982, pp. 77-87 Chapter 11, Eds. Mariani, Russo and Mandelli, Praeger Publishers, U.S.A.
Fair, D.S. and Bahnak, B.R. “Human Hepatoma Cells Secrete Single Chain Factor S. Prothombin and Antithrombin III.”Blood,Jul. 1984, pp. 194-204, vol. 64, No. 1.
Fischer et al “Structural Analysis of Recombinant von Willebrand Factor: Identification of hetero- and homo-cimers”,FEBS Lett.,1994, pp 345-348, vol. 351.
Fung, M. et al. “Characterization of an almost full-length cDNA coding for human blood coagulation factor X”Proc. Natl. Acad. Sci. USA,Jun. 1985, pp. 3591-3595, vol. 82.
Giles, A. et al. “A combination of factor Xa and phosphatidvicholine-phosphatidylserine vesicles bypasses factor VIII in vivo.”British J. Haemotology,1988, pp. 491-497, vol. 69.
Gordon, V.M. et al. “Proteolytic Activation of Bacterial Toxins by Eukaryotic Cells is Performed by Furin and by Additional Cellular Proteases.”Infec. Immunol.,1995, pp. 82-87, vol. 63.
Himmelspach, M. et al. “Alteration of the Specificity of fX Activation by Substitution of Amino Acids Constituting its Activation Site”,XVII Congress of the International Society on Thrombosis and Haemostasis,1999, p. 758.
Jesty, J. et al. “The Mechanism of Activation of Factor X Kinetic Control of Alternative Pathways Leading to the Formation of Activated Factor X”J. Biol. Chem.,Sep. 10, 1974, pp 5614-5622, vol. 249, No. 17.
Leytus, S. et al. “Characterization of cDNA coding for human factor X”Proc. Natl. Acad. Sci. USA,Jun. 1984, pp. 3699-3702, vol. 81.
Leytus, S. et al. “Gene for Human Factor S: A Blood Coagulation Factor Whose Gene Organization is Essentially dentical with that of Factor IX and Protein C”Biochem.,1986, pp. 5098-5102, vol. 25.
Mertens, K. & Bertina, R. “Pathways in the Activation of Human Coagulation Factor X”Biochem. J.,1980, pp. 647-658, vol. 185.
Messier, T. et al. “Cloning and expression in COS-1 cells of a full-length cDNA encoding human coagulation factor X”Gene,1991, pp. 291-294, vol. 99. E sevier.
Moehring, J.M. & Meohring, T.J. “Strains of CHO-K1 Cells Resistant to Pseudomonas Exotoxin A and Cross-Resistant to Diphtheria Toxin and Viruses”Infection and Immunity,1983, pp. 998-1009, vol. 41.
Morita et al. “Structural and Functional Characteristics of a Proteolytically Modified ‘Gla Domain-less’ Bovine Factor X and Xa (des light chain residues 1-14).”General Biochem.,1980, p. 219, vol. 92, Abstract No. 92:71374k.
Ngo et al.Computational Complexity, Protein Structure Prediction and the Levinthal Paradox in the Protein Folding Problem and Tertiary Structure.1994, Eds. K. Mez. Jr. and Le Grand, Birkhauser, Boston.
Ohnishi Y. et al. “A Furin-Defective Cell Line is Able to Process Correctly the gp160 of Human Immunodeficiency Virus Type 1.”J. Virol.,1994, pp. 4075-4079, vol. 68.
Pryzdial, E. & Kessler, G. “Autoproteolysis or Plasmin-mediated Cleavage of Factor Xaα Exposes a Plasminogen Binding Site and Inhibits Coagulation.”J. Biol. Chem.,Jul. 12, 1996, pp. 16614-16620, vol. 271 No. 28.
Pryzdial, E. & Kessler, G. “Kinetics of Blood Coagulation oFactor Xaα Autoprotcolytic Conversion of Factor Xaβ”J. Biol. Chem.,Jul. 12, 1996, pp. 16621-16626, vol. 271, No. 28.
Rehemtulla, A. & Kaufman, R.J. “Preferred Sequence Requirements for Cleavage of Pro-von Willebrand Factor by Propeptide-Processing Enzymes.”Blood,1992, pp. 2349-2355, vol. 79.
Rudolph, A.E. et al. “Expression, Purification and Characterization of Recombinant Human Factor X1.”Protein Expression and Purification,1997 pp. 373-378, vol. 10.
Sherrill, G.B. et al. “Inactivation of Human Blood Coagulation Factor X by Chemical Modification of Gamma-Carboxyglutamic Acid Residues,”0Enzymes,1985, p. 239, vol. 102, Abstract No. 102:2489q.
Teng. C. & Seegers, W. “Production of factor X and factor Xa variants with thrombin, acutin and by autolysis.”Thrombosis Research1981, pp. 213-220, vol. 22.
Urlaub, G. & Chasin, L. “Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity.”Proc. Natl. Acad. Sci. USA,Jul. 1980, pp. 4216-4220, vol. 77, No. 7.
Wallin, R. et al. “Intracellular Proteolytic Processing of the Two-Chain Vitamin K-Dependent Coagulation Factor X”Thrombosis Res.,1994, pp. 395-403, vol. 73.
Watzke, H. & High, K “Factor X ”Molecular Basis of Thrombosis and Hemostasis,1995, pp. 239-255, Chapter 11, Eds. High and Roberts.
Wells et al. “Additivity of Mutational Effects In Proteins.”Biochemistry,1990, pp. 8509-8517, vol. 29, No. 37.
Wolf, D. et al. “Design of Constructs for the Expression of Biologically Active Recombinant Human Factors X and Xa”J. Biol. Chem.,Jul. 25, 1991, pp. 13726-13730, vol. 266, No. 21.

Affiliated with

Also associated with

Rating

Factor X analog with an improved ability to be activated does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Factor X analog with an improved ability to be activated, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Factor X analog with an improved ability to be activated will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3477541